Tango Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
TNGX$22.74+5.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $112,279 | $69,530 |
| Marketable securities | 230,859 | 188,387 |
| Restricted cash | 428 | — |
| Prepaid expenses and other current assets | 10,190 | 8,426 |
| Total current assets | 353,756 | 266,343 |
| Property and equipment, net | 6,868 | 8,102 |
| Operating lease right-of-use assets | 35,624 | 39,476 |
| Restricted cash, net of current portion | 2,139 | 2,567 |
| Other assets | 303 | 4 |
| Total assets | $398,690 | $316,492 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,182 | $1,601 |
| Accrued expenses and other current liabilities | 17,759 | 16,497 |
| Operating lease liabilities | 2,738 | 2,454 |
| Deferred revenue | — | 17,618 |
| Total current liabilities | 21,679 | 38,170 |
| Operating lease liabilities, net of current portion | 30,832 | 34,039 |
| Deferred revenue, net of current portion | — | 44,766 |
| Total liabilities | 52,511 | 116,975 |
| Commitments and contingencies (Note 8) | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and 2024, respectively | — | — |
| Stockholders' equity: | ||
| Common stock, $0.001 par value; 400,000,000 and 200,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 135,940,454 and 107,729,343 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 136 | 108 |
| Additional paid-in capital | 948,971 | 700,631 |
| Accumulated other comprehensive income | 224 | 336 |
| Accumulated deficit | (603,152) | (501,558) |
| Total stockholders’ equity | 346,179 | 199,517 |
| Total liabilities and stockholders’ equity | $398,690 | $316,492 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.